ArticleChemMedChem2026
New 1,3-Oxazole and 1,2,4-Oxadiazole Derivatives as Novel Agents Against Human Rhinovirus and Cytomegalovirus.
Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A library of 16 new five-functionalized derivatives of 2-undecyl- and 1,2,4-oxadiazole-containing 2-aryl-4-cyano-1,3-oxazoles was synthesized using α-acylamino-β,β-dichloroacrylonitriles as key building blocks, enabling efficient formation of diverse 1,3-oxazole, oxadiazole-oxazole, and sulfonamide-oxazole systems. The antiviral potential was evaluated in vitro against rhinovirus 8 (HRV8), cytomegalovirus (HCMV), parainfluenza virus type 3 (HPIV-3), and zoonotic encephalomyocarditis virus (EMCV). Screening revealed distinct activity profiles: none of the compounds inhibited EMCV or HPIV-3, while several demonstrated pronounced efficacy against HRV8 and HCMV. In concentration-dependent assays, compounds 1, 7, 10, 13, and 14 exhibited potent anti-HCMV effects (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.